NorthWest Biotherapeutics Inc (NWBO)

[longfellow95]

'Remission rate' apparently.

“Kymriah is a first-of-its-kind treatment approach that fills an important unmet need for children and young adults with this serious disease,” said Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research (CBER). “Not only does Kymriah provide these patients with a new treatment option where very limited options existed, but a treatment option that has shown promising remission and survival rates in clinical trials.”

The safety and efficacy of Kymriah were demonstrated in one multicenter clinical trial of 63 pediatric and young adult patients with relapsed or refractory B-cell precursor ALL. The overall remission rate within three months of treatment was 83 percent.

“Kymriah is a first-of-its-kind treatment approach that fills an important unmet need for children and young adults with this serious disease,” said Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research (CBER). “Not only does Kymriah provide these patients with a new treatment option where very limited options existed, but a treatment option that has shown promising remission and survival rates in clinical trials.”

https://www.drugs.com/newdrugs/fda-approves-kymriah-tisagenlecleucel-car-t-gene-therapy-acute-lymphoblastic-leukemia-4588.html

Yescarta also 'remission rate'.
https://www.drugs.com/newdrugs/fda-approves-kymriah-tisagenlecleucel-car-t-gene-therapy-acute-lymphoblastic-leukemia-4588.html

No telling how long the remission lasted.